Intellia Therapeutics (NTLA) Tops Q1 EPS by 23c

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($1.17), $0.23 better than the analyst estimate of ($1.40). Revenue for the quarter came in at $12.61 million versus the consensus estimate of $11.66 million.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Worthington Enterprises raises dividend 5%, adds board member
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook